{"id":62057,"date":"2025-10-20T19:06:45","date_gmt":"2025-10-20T17:06:45","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\/"},"modified":"2025-10-20T19:06:45","modified_gmt":"2025-10-20T17:06:45","slug":"meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\/","title":{"rendered":"Meitheal Pharmaceuticals to Present New Data in Infectious Disease Portfolio at IDWeek 2025"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<i>New data examining fosfomycin for injection\u2019s ability to treat acute pyelonephritis (AP) and complicated urinary tract infections (cUTIs) to be presented in three poster sessions<\/i><\/li>\n<li>\n<i>Additional analyses from Phase 2\/3 ZEUS clinical trial of fosfomycin for injection for cUTI to be shared<\/i><\/li>\n<li>\n<i>Breadth of data presented demonstrates fosfomycin for injection\u2019s effectiveness in combatting infections and Meitheal\u2019s commitment to addressing the ongoing threat of antibiotic resistance<\/i><\/li>\n<\/ul>\n<p>CHICAGO&#8211;(BUSINESS WIRE)&#8211;Meitheal Pharmaceuticals, Inc. (\u201cMeitheal\u201d), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products will share new antibiotic data at the 14<sup>th<\/sup> annual IDWeek in Atlanta, GA, from October 19-22, 2025. Meitheal\u2019s presentations will include clinical trial data updates on the safety and effectiveness of fosfomycin for injection for the treatment of complicated urinary tract infections (cUTI), including acute pyelonephritis (AP).<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20251020126688\/en\/2176260\/5\/Meitheal-logo-June-2024.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251020126688\/en\/2176260\/22\/Meitheal-logo-June-2024.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20251020126688\/en\/2176260\/5\/Meitheal-logo-June-2024.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251020126688\/en\/2176260\/21\/Meitheal-logo-June-2024.jpg\"><\/a><\/p>\n<p>\nTwo of the three poster sessions at IDWeek will feature subsequent analysis from the Phase 2\/3 ZEUS clinical trial of fosfomycin for injection including a subgroup analysis of patients with a high burden of chronic illness and severe acute disease, and a post-hoc analysis of the clinical pathogens and microbiological outcomes following treatment. Additionally, Meitheal will present findings from an additional assessment of fosfomycin for injection\u2019s disk diffusion against resistant Enterobacterales.<\/p>\n<p>\n\u201cWe are extremely excited about the data being presented at IDWeek 2025. The escalating public health issue of antimicrobial resistance and emergence of highly resistant organisms demands immediate attention and innovative therapeutic solutions,\u201d said Dr. Keith Robinson, Chief Medical Officer of Meitheal Pharmaceuticals. \u201cThe clinical evidence highlights fosfomycin for injection\u2019s therapeutic potential to address infectious diseases, make a difference for patients, and address an unmet need in the current antibiotic treatment landscape.\u201d<\/p>\n<p>\n<b>Poster Presentations during IDWeek 2025:<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth50\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Abstract Title<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwwidth50\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Presentation Details<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth50\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nImpact of Increased Severity of Illness on Outcomes in Complicated Urinary Tract Infections (cUTI) from ZEUS, a Randomized Controlled Trial (RCT) Evaluating IV Fosfomycin (IV-FOS)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth50\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPoster Session: A6. New Drug Development<\/p>\n<p class=\"bwcellpmargin\">\nPoster Number: P-1170<\/p>\n<p class=\"bwcellpmargin\">\nDate: Tuesday, October 21, 2025<\/p>\n<p class=\"bwcellpmargin\">\nTime: 12:15 \u2013 1:30pm ET<\/p>\n<p class=\"bwcellpmargin\">\nLocation: Poster Hall B4-B5<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth50\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAssessment of the fosfomycin 200 \u00b5g disk diffusion against resistant Enterobacterales: data from the intravenous fosfomycin (IV-FOS) clinical trial program for complicated urinary tract infection<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth50\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPoster Session: A6. New Drug Development<\/p>\n<p class=\"bwcellpmargin\">\nPoster Number: P-1171<\/p>\n<p class=\"bwcellpmargin\">\nDate: Tuesday, October 21, 2025<\/p>\n<p class=\"bwcellpmargin\">\nTime: 12:15 \u2013 1:30pm ET<\/p>\n<p class=\"bwcellpmargin\">\nLocation: Poster Hall B4-B5<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth50\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCharacterization of Clinical Pathogens and Microbiological Outcomes for patients treated with IV Fosfomycin (IV-FOS) in the ZEUS Phase 2\/3 Complicated Urinary Tract Infection, including Acute Pyelonephritis (cUTI\/AP) Trial<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth50\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPoster Session: A6. New Drug Development<\/p>\n<p class=\"bwcellpmargin\">\nPoster Number: P-1172<\/p>\n<p class=\"bwcellpmargin\">\nDate: Tuesday, October 21, 2025<\/p>\n<p class=\"bwcellpmargin\">\nTime: 12:15 \u2013 1:30pm ET<\/p>\n<p class=\"bwcellpmargin\">\nLocation: Poster Hall B4-B5<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\nMeitheal previously acquired United States rights to fosfomycin for injection from Nabriva Therapeutics in July 2024. A decision from the U.S. Food &amp; Drug Administration on a New Drug Application for fosfomycin for injection is expected this year.<\/p>\n<p>\n<b>ABOUT FOSFOMYCIN FOR INJECTION<br \/>\n<br \/><\/b>Fosfomycin for injection is the only antibiotic in the phosphonics class of antibiotics. This class is bactericidal, uniquely inhibiting the first step in bacterial cell wall synthesis with activity against antimicrobial resistant (AMR) pathogens. This results in low resistance rates and no known cross-resistance to other antibiotic classes. Supported by over 40 years of global use, fosfomycin for injection has proven clinical efficacy and safety for the treatment of adult patients with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP).<\/p>\n<p>\n<b>ABOUT MEITHEAL PHARMACEUTICALS, INC.<br \/>\n<br \/><\/b>Founded in 2017 and based in Chicago, Meitheal is focused on the development and commercialization of generic injectable medications and, as of 2022, has expanded its focus to include fertility, biologic, and branded products. Meitheal currently markets over 70 U.S. FDA-approved products across numerous therapeutic areas including anti-infectives, oncolytics, intensive care, and fertility. As of October 2025, Meitheal, directly or through its partners, has 46 products in the research and development phase, 9 additional products planned for launch in 2025, 4 products in clinical trial phases, and 23 products under review by the FDA. Meitheal\u2019s mission is to provide easy access to fairly priced products through robust manufacturing, consistent supply, and rapid response to our customers\u2019 needs. Ranked regularly as one of Crain\u2019s Fast 50 in Chicago, and in the top 100 of Crain\u2019s Best Places to Work in Chicago from 2022 to 2025, Meitheal emulates the traditional Irish guiding principle we are named for\u2014working together toward a common goal, for the greater good.<\/p>\n<p>\nLearn more about who we are and what we do at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.meithealpharma.com&amp;esheet=54341020&amp;newsitemid=20251020126688&amp;lan=en-US&amp;anchor=www.meithealpharma.com&amp;index=1&amp;md5=3da948794697d8baaec27508db19dfc5\" rel=\"nofollow\" shape=\"rect\">www.meithealpharma.com<\/a>.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>MEDIA CONTACT<\/b><br \/>Meitheal Pharmaceuticals, Inc.<br \/>\n<br \/>John Spilman, VP of Corporate Strategy<br \/>\n<br \/>773 899 5910<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#x6c;t&#111;&#x3a;&#105;&#x6e;f&#111;&#x40;&#109;&#x65;i&#x74;&#x68;&#101;&#x61;l&#x70;h&#97;&#x72;&#109;&#x61;&#46;&#99;&#x6f;&#109;\" rel=\"nofollow\" shape=\"rect\">info&#64;&#109;&#101;&#105;&#116;&#104;&#101;&#x61;&#x6c;&#x70;&#x68;&#x61;&#x72;&#x6d;&#x61;&#x2e;com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>New data examining fosfomycin for injection\u2019s ability to treat acute pyelonephritis (AP) and complicated urinary tract infections (cUTIs) to be presented in three poster sessions Additional analyses from Phase 2\/3 ZEUS clinical trial of fosfomycin for injection for cUTI to be shared Breadth of data presented demonstrates fosfomycin for injection\u2019s effectiveness in combatting infections and &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62057","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Meitheal Pharmaceuticals to Present New Data in Infectious Disease Portfolio at IDWeek 2025 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Meitheal Pharmaceuticals to Present New Data in Infectious Disease Portfolio at IDWeek 2025 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"New data examining fosfomycin for injection\u2019s ability to treat acute pyelonephritis (AP) and complicated urinary tract infections (cUTIs) to be presented in three poster sessions Additional analyses from Phase 2\/3 ZEUS clinical trial of fosfomycin for injection for cUTI to be shared Breadth of data presented demonstrates fosfomycin for injection\u2019s effectiveness in combatting infections and ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-20T17:06:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251020126688\/en\/2176260\/22\/Meitheal-logo-June-2024.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Meitheal Pharmaceuticals to Present New Data in Infectious Disease Portfolio at IDWeek 2025\",\"datePublished\":\"2025-10-20T17:06:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\\\/\"},\"wordCount\":755,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251020126688\\\/en\\\/2176260\\\/22\\\/Meitheal-logo-June-2024.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\\\/\",\"name\":\"Meitheal Pharmaceuticals to Present New Data in Infectious Disease Portfolio at IDWeek 2025 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251020126688\\\/en\\\/2176260\\\/22\\\/Meitheal-logo-June-2024.jpg\",\"datePublished\":\"2025-10-20T17:06:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251020126688\\\/en\\\/2176260\\\/22\\\/Meitheal-logo-June-2024.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251020126688\\\/en\\\/2176260\\\/22\\\/Meitheal-logo-June-2024.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Meitheal Pharmaceuticals to Present New Data in Infectious Disease Portfolio at IDWeek 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Meitheal Pharmaceuticals to Present New Data in Infectious Disease Portfolio at IDWeek 2025 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\/","og_locale":"en_US","og_type":"article","og_title":"Meitheal Pharmaceuticals to Present New Data in Infectious Disease Portfolio at IDWeek 2025 - Pharma Trend","og_description":"New data examining fosfomycin for injection\u2019s ability to treat acute pyelonephritis (AP) and complicated urinary tract infections (cUTIs) to be presented in three poster sessions Additional analyses from Phase 2\/3 ZEUS clinical trial of fosfomycin for injection for cUTI to be shared Breadth of data presented demonstrates fosfomycin for injection\u2019s effectiveness in combatting infections and ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\/","og_site_name":"Pharma Trend","article_published_time":"2025-10-20T17:06:45+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251020126688\/en\/2176260\/22\/Meitheal-logo-June-2024.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Meitheal Pharmaceuticals to Present New Data in Infectious Disease Portfolio at IDWeek 2025","datePublished":"2025-10-20T17:06:45+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\/"},"wordCount":755,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251020126688\/en\/2176260\/22\/Meitheal-logo-June-2024.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\/","url":"https:\/\/pharma-trend.com\/en\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\/","name":"Meitheal Pharmaceuticals to Present New Data in Infectious Disease Portfolio at IDWeek 2025 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251020126688\/en\/2176260\/22\/Meitheal-logo-June-2024.jpg","datePublished":"2025-10-20T17:06:45+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251020126688\/en\/2176260\/22\/Meitheal-logo-June-2024.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251020126688\/en\/2176260\/22\/Meitheal-logo-June-2024.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Meitheal Pharmaceuticals to Present New Data in Infectious Disease Portfolio at IDWeek 2025"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62057","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62057"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62057\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62057"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62057"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62057"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}